In the U.S., the rise in healthcare costs has been the subject of intense public and regulatory scrutiny. Average health insurance premiums have risen steadily over the past few years, outpacing inflation. However, the negative consequences of this economic rise are not fully understood. In particular, a significant portion of the rise in healthcare costs… Read More »
The antitrust world is changing. US agencies’ eyes are turning to finance, with the newest enforcement target being private equity (“PE”). Repeated public statements and speeches of US antitrust officials under the Biden administration clearly signal this policy shift. This is no surprise for Europe. The European Commission, confirmed by the Courts, has also recently… Read More »
In my recent paper, I study whether and how private equity (PE) fund investors (hereafter general partners or GPs) manipulate their fund performance during fundraising periods. Recent studies (i) have found abnormally high PE fund valuations during fundraising periods and (ii) have debated (but have not settled) whether these valuations reflect manipulating the existing funds’… Read More »
Private equity firms have been a mainstay of the mergers and acquisitions (“M&A”) industry for decades. Private equity firms are in the business of acquiring companies and subsequently selling them, ideally at a higher price. Those returns are then distributed to the investors of the underlying private equity fund after the private equity firm has… Read More »
For an industry built around “diversification,” we still have plenty of work to do to apply the concept to our investment teams. We know that if you restrict a portfolio, you can’t always maximize performance, so isn’t it reasonable to consider that the same might hold for talent diversity and team performance? The composition of… Read More »
